Ultima-Oxy 50 mg 50 Tablets Ultima Pharma USA

Product Overview

Ultima Pharma USA’s Oxy 50 mg presents oxymetholone, featuring 2-hydroxymethylene-17α-methyl substitution characteristic of first-generation oral anabolics (~8-9 hour half-life), in USP-equivalent elliptical scored tablets identical to Schedule III Anadrol-50 morphology for seamless institutional catalog integration. The 50-tablet HDPE bottle configuration with child-resistant cap replicates CIII pharmacy dispensing standards supporting DEA Form 222 inventory protocols across encrypted specialist platforms serving advanced performance resellers.

U.S. domestic manufacturing through GMP facilities maintains exact molecular specifications (MW 332.48, C21H32O3) distinguishing legitimate Schedule III supply from underground powder conversions prevalent across non-pharmaceutical channels. This authentic 50 mg/50-tab presentation serves institutional buyers requiring verified potency declaration and batch traceability essential for controlled substance compliance workflows rather than generic or international grey-market alternatives exposing end-users to customs seizure and authenticity uncertainty.

Ultima-Oxy positions exclusively within verified DEA Schedule III ecosystems targeting licensed institutional clientele familiar with high-potency 17α-alkylated anabolic management protocols, emphasizing commercial verification infrastructure over therapeutic or recreational crossover applications without dosing guidance, cycle recommendations, or outcome representations.​

Brand & Manufacturer Information

Ultima Pharma USA manufactures DEA Schedule III controlled substances through U.S.-domiciled GMP-compliant facilities serving institutional performance distribution networks requiring rigorous controlled substance compliance protocols. Oxy 50 mg completes Ultima’s high-potency oral catalog alongside Stan/Superdrol maintaining dosage continuum (10→25→50 mg) enabling precise institutional SKU differentiation while USP-equivalent tablet morphology and CIII-compliant bottling authenticate legitimate supply chains versus powder-pressed underground alternatives universally rejected by DEA-registered resellers.

Domestic warehousing infrastructure supports encrypted Form 222 fulfillment across U.S. specialist platforms eliminating international customs exposure while published batch analytics verify 50 mg oxymetholone identity/potency through independent HPLC confirmation distinguishing Ultima from non-pharmaceutical brands lacking controlled substance pedigree.​

Active Compound Information

Contains oxymetholone (17β-hydroxy-2-(hydroxymethylene)-17α-methyl-5α-androstan-3-one), first-generation 17α-alkylated anabolic-androgenic steroid derived from DHT exhibiting potent erythropoietic stimulation alongside mass-gaining properties characteristic of 2-hydroxymethylene modification enabling oral bioavailability without 17-keto reduction. DEA Schedule III classification under 21 CFR 1308.13 reflects hepatotoxicity profile, cardiovascular risk factors, and performance dosage escalation potential beyond original prescription indications discontinued post-2006 FDA withdrawal of Oxandrin/Anadrol approvals.

50 mg strength precisely matches historical Anadrol-50 (Alaven Pharmaceutical) specifications while 50-tablet count replicates CIII pharmacy dispensing units supporting institutional inventory rotation protocols. Molecular formula C21H32O3; WADA S1.1a prohibited year-round across all competitive categories globally.​

Product Specifications

Quality Control & Testing Standards

50 mg oxymetholone mandates USP <621> potency assay (90-110% HPLC label claim), USP <711> dissolution (Q=80% within 30 minutes), USP <905> uniformity, and USP <621> related substances testing confirming pharmaceutical-grade specifications matching historical Anadrol-50 monographs. Ultima batch documentation includes independent third-party CoA verifying C21H32O3 identity through IR spectroscopy, chiral purity, and absence of 17-epimer degradation products distinguishing legitimate GMP production from underground conversions universally exhibiting potency variance >±25%.

Institutional 50-tablet bottling incorporates USP <671> moisture permeation barriers preventing hygroscopic degradation characteristic of oxymetholone while child-resistant closure satisfies CFR 21 310.310(a) packaging requirements for Schedule III dispensaries. Domestic climate-controlled warehousing maintains 36-month accelerated stability per ICH Q1A(R2) protocols exceeding underground alternatives prone to 30-50% potency loss within 6 months post-manufacture.​

Intended Use & Market Positioning

Ultima-Oxy 50 mg 50 Tablets serves DEA-registered institutional performance researchers and CIII-licensed bulk resellers managing high-potency Schedule III anabolic inventories exclusively through encrypted fulfillment networks requiring Form 222 compliance documentation. Exact Anadrol-50 replication excludes pharmaceutical crossover positioning within premium domestic catalogs serving verified institutional clientele demonstrating controlled substance handling protocols.

No administration regimens, cycle lengths, stacking protocols, PCT requirements, or therapeutic outcomes represented or implied across institutional specifications maintaining strict commercial positioning devoid of medical guidance characteristic of legitimate CIII distribution workflows.​

Legal & Regulatory Disclaimer

Oxymetholone constitutes DEA Schedule III controlled substance under 21 USC §812 Controlled Substances Act with non-medical manufacture, distribution, possession, or importation subject to federal penalties including up to 5 years imprisonment/$250,000 fines per 21 U.S.C. § 841 plus mandatory enhanced sentencing for repeat violations or quantities exceeding 5 grams pure (21 U.S.C. § 841(b)(1)(D)).

Institutional purchasers assume complete responsibility for DEA registrant status verification, Form 222 triplicate documentation, state pharmacy board licensing, triennial inventory reconciliation, and local jurisdictional compliance across all 50 U.S. states plus territories. No medical claims, dosing recommendations, cycle protocols, therapeutic indications, or performance outcomes provided or implied; product positioned exclusively as commercial controlled substance for DEA-registered institutional handling per 21 CFR 1301.13 registrant requirements.​